X4 Pharmaceuticals, Inc. (XFOR) News
Follow X4 Pharmaceuticals, Inc. (XFOR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
X4 Pharmaceuticals reports Q3 loss
X4 Pharmaceuticals reported a loss for the third quarter.
EQUITY | Nov 04, 2026, 09:33 PM UTC
M
X4 Pharmaceuticals Reports Third-Quarter 2026 Results and Corporate Update
The update says the 4WARD Phase 3 chronic neutropenia trial is expected to achieve target enrollment in Q4 2026.
EQUITY | Nov 04, 2026, 09:15 PM UTC
M
X4 Pharmaceuticals Q3 Results Due October 29; EPS Estimate Is a Loss
X4 Pharmaceuticals is expected to report Q3'26 results on October 29. Estimates call for a loss per share and revenue; the release time is not specified.
EQUITY | Oct 28, 2026, 11:04 AM UTC
L
X4 Pharmaceuticals Phase III enrollment nears completion for mavorixafor
Mavorixafor’s Phase III trial for chronic neutropenia is on track with a reduced enrollment target and strong FDA alignment. X4 Pharmaceuticals says operational changes improved enrollment, with a new study to address G-
REGULATION | Sep 10, 2026, 02:41 PM UTC
L
XFOR nears Phase III mavorixafor enrollment completion
XFOR says its Phase III trial for chronic neutropenia is on track to complete enrollment by year-end. Top-line data is expected in early 2028, with a new G-CSF titration study planned and commercial launch targeted for l
EQUITY | Sep 10, 2026, 02:15 PM UTC
L
X4 Pharmaceuticals to join fireside chat at Wells Fargo Healthcare Conference
X4 Pharmaceuticals said management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10.
EQUITY | Sep 09, 2026, 11:03 AM UTC
L
XFOR - X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
XFOR - X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
EQUITY | Sep 09, 2026, 11:00 AM UTC
L
X4 posts updated presentation, flags 4WARD timelines
X4 posted an updated corporate presentation saying full enrollment for its pivotal 4WARD Phase 3 study is expected in Q4 2026, with topline data expected in H1 2028.
REGULATION | Sep 09, 2026, 10:04 AM UTC
M
FDA accepts reduced sample size for X4’s 4WARD Phase 3
X4 Pharmaceuticals said the FDA agreed to reduce 4WARD Phase 3 to 126 patients, accepted the proposed safety database, and the company targets enrollment completion by year-end 2026.
REGULATION | Sep 08, 2026, 11:23 AM UTC
M
X4 Pharmaceuticals gets positive FDA input on 4WARD Phase 3 trial
FDA agreed to a reduced sample size for X4 Pharmaceuticals’ Global 4WARD Phase 3 chronic neutropenia trial. Enrollment is expected to complete by year-end 2026, with topline data due in H1 2028.
REGULATION | Sep 08, 2026, 11:07 AM UTC
M
X4 Pharmaceuticals announces positive FDA Type C meeting outcome
X4 Pharmaceuticals said its FDA Type C meeting outcome was positive.
REGULATION | Sep 08, 2026, 11:01 AM UTC
L
X4 Pharmaceuticals announces inducement grants under Nasdaq Rule 5635(c)(4)
X4 Pharmaceuticals said it is announcing inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 08:31 PM UTC
H
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Airsculpt Technologies Inc (NASDAQ: AIRS ) fell sharply in pre-market trading following second-quarter results. Ai
EARNINGS | Aug 10, 2026, 12:02 PM UTC